Which clinical trials are running late?
A live map of 9,180 industry trials, with every readout date checked against the one first registered. Plus FDA approvals, recalls and warning letters, matched to the sponsors.
Free · refreshed nightly from ClinicalTrials.gov and the FDA (data as of 2026-11-18) · not investment or medical adviceAlmost half of trials push their readout back by more than six months.
ClinicalTrials.gov keeps every version of every record. Comparing the readout date each trial was first registered with against today's, across 5,378 active trials registered over a year ago, 46% have moved it by more than six months.
How every sponsor compares →Latest activity
View the event log →Next Phase 3 readouts
Calendar →Five ways to read the pipeline
Delay Index
Sponsors and stock tickers ranked by how often their readouts slip, by disease area, with the biggest moves listed. Every trial shows its originally planned date next to today's.
Open the Delay Index →Live trial map
Every Phase 2–3 industry trial at its sites, by phase and area, or coloured by delay. Filter GLP-1, ADCs, Alzheimer's or Big Pharma, or search any drug, sponsor or $ticker.
Open the map →FDA and manufacturing signals
New approvals, recalls, shortages and 1,114 warning letters to drug and biologics makers, matched to the sponsors on the map. 135 were about manufacturing (CGMP) in the last 12 months.
Open FDA watch →Readout calendar
Every upcoming Phase 3 primary completion, or one company's, in Google, Outlook or Apple Calendar. It updates itself every night.
Subscribe →The daily Radar Report
One page each morning: readouts due in two weeks, what changed in the registry, delay leaders, FDA news and new Phase 3 trials.
Read today's report →Most often late
Sponsors with 10+ active trials registered over a year ago| SPONSOR | TRIALS | SLIPPED 6+ MONTHS |
|---|---|---|
| Acerta Pharma BV | 11 | 91% |
| Ionis Pharmaceuticals, Inc. $IONS | 12 | 83% |
| Taiho Oncology, Inc. | 10 | 70% |
| Allist Pharmaceuticals, Inc. | 12 | 67% |
| Seagen, a wholly owned subsidiary of Pfizer $PFE | 12 | 67% |
About the data
Trials come from ClinicalTrials.gov (U.S. National Library of Medicine), including each record's version history. FDA approvals, recalls and shortages come from openFDA; warning letters from fda.gov. Everything is rebuilt every night, and every daily snapshot is kept.
Dates are reported by sponsors and are often estimates. A slipped date isn't necessarily bad news; a study may simply have grown. Records the sponsor has stopped maintaining are flagged and left out of the Delay Index.











